to

Reset filters

Editorial Commentary: Phage Therapy: Quo Vadis?

Editorial Commentary: Phage Therapy: Quo Vadis? EDIT ORIAL C OMMENTAR Y Phage Therapy: Quo Vadis? Harald Brüssow Nutrition and Health Department, Human Microbiology Group, Nestlé Research Center, Lausanne, Switzerland (See the Review Article by Knoll and Mylonakis on pages 528–34.) Keywords. bacteriophages; antimicrobials; bacterial infections; diarrhea; therapy. In this issue of Clinical Infectious Diseas- and phage-enthusiasts, where the former of interest of the pharmaceutical industry es, Knoll and Mylonakis provide a ba- dismiss phage therapy as a “Stalinist for phage therapy could be explained lanced review on the phage therapy cure” and the latter praise phages as a by the fact that phage products would literature. Their review covers both repli- time-honored medicine. Skeptical scien- cannibalize antibiotic selling and thus be cation-competent phages and biotechno- tists point to the lack of published scien- commercially counterproductive for this logically produced lytic phage enzymes tific information on the efficacy of phage industry. The difficulty of patent protec- as antimicrobial agents. The authors, and therapy. Indeed, Knoll and Mylonakis do tion for phage therapy approaches has the editors of CID, are to be lauded for not quote a single phage paper from been identified as another reason dis- this timely review as phages and their Eastern Europe. This http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Infectious Diseases Oxford University Press

Editorial Commentary: Phage Therapy: Quo Vadis?

2 pages
Read Article

Loading next page...
 
/lp/oxford-university-press/editorial-commentary-phage-therapy-quo-vadis-2TZ7hnTFFx
Publisher
Oxford University Press
Copyright
The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Subject
REVIEW ARTICLES
ISSN
1058-4838
eISSN
1537-6591
D.O.I.
10.1093/cid/cit776
Publisher site
See Article on Publisher Site

Abstract

EDIT ORIAL C OMMENTAR Y Phage Therapy: Quo Vadis? Harald Brüssow Nutrition and Health Department, Human Microbiology Group, Nestlé Research Center, Lausanne, Switzerland (See the Review Article by Knoll and Mylonakis on pages 528–34.) Keywords. bacteriophages; antimicrobials; bacterial infections; diarrhea; therapy. In this issue of Clinical Infectious Diseas- and phage-enthusiasts, where the former of interest of the pharmaceutical industry es, Knoll and Mylonakis provide a ba- dismiss phage therapy as a “Stalinist for phage therapy could be explained lanced review on the phage therapy cure” and the latter praise phages as a by the fact that phage products would literature. Their review covers both repli- time-honored medicine. Skeptical scien- cannibalize antibiotic selling and thus be cation-competent phages and biotechno- tists point to the lack of published scien- commercially counterproductive for this logically produced lytic phage enzymes tific information on the efficacy of phage industry. The difficulty of patent protec- as antimicrobial agents. The authors, and therapy. Indeed, Knoll and Mylonakis do tion for phage therapy approaches has the editors of CID, are to be lauded for not quote a single phage paper from been identified as another reason dis- this timely review as phages and their Eastern Europe. This

Journal

Clinical Infectious Diseases – Oxford University Press

Published: Feb 15, 2014

Keywords: bacteriophages antimicrobials bacterial infections diarrhea therapy

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off

Sign up
for free
Start 14 day
Free Trial